Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00982202 · ClinicalTrials.gov registry record · Phase 2
Pioglitazone in Alzheimer Disease
A Phase 2 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00982202 is a Phase 2 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 25 participants.
The verdict
NCT00982202, a Phase 2 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study was designed to assess the safety and tolerability of pioglitazone, an approved drug for type 2 diabetes, in non diabetic patients with Alzheimer's disease. It was also designed to generate preliminary information on whether pioglitazone might slow progression of Alzheimer's disease.
Interventions
- DRUG Placebo
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2002-01 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00982202
The ClinicalTrials.gov registry entry for NCT00982202 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00982202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00982202 about?
NCT00982202 is a clinical study titled "Pioglitazone in Alzheimer Disease". This study was designed to assess the safety and tolerability of pioglitazone, an approved drug for type 2 diabetes, in non diabetic patients with Alzheimer's disease. It was also designed to generate preliminary information on whether pioglitazone might slow progression of Alzheimer's disease.
What is the current status of trial NCT00982202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2002-01. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00982202?
The interventions under investigation include: Placebo (DRUG), pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00982202?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.